医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HighTide to Present at the BofA Securities 2021 Health Care Conference

2021年04月28日 PM11:00
このエントリーをはてなブックマークに追加


 

SHENZHEN, China & ROCKVILLE, Md.

HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that Company’s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.

HighTide will present at 8:00am EDT on Thursday, May 13, 2021.

About HighTide Therapeutics

HighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on areas of high unmet medical need and lack of effective treatment options.

About HTD1801

HighTide’s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a first-in-class drug and new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC). HTD1801 has received Fast Track designation from the U.S. FDA for both PSC and NASH, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005045/en/

CONTACT

Investor relations:

Jeffrey Dao

ir@hightidetx.com

Media relations:

Grace Zhang

media@hightidetx.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024